Detects equine IL-5 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 50% cross-reactivity with recombinant bovine IL-5 and recombinant feline IL-5 is observed, 30% cross-reactivity with recombinant mouse IL-5 and recombinant canine IL-5 is observed, 20% cross-reactivity with recombinant rhesus macaque IL-5 is observed, and less than 10% cross-reactivity with recombinant rat IL-5 and recombinant porcine IL-5 is observed.
Measured by its ability to neutralize IL‑5-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 0.5-2.0 µg/mL in the presence of 50 ng/mL Recombinant Equine IL‑5.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Cell Proliferation Induced by IL‑5 and Neutralization by Equine IL‑5 Antibody.
Recombinant Equine IL‑5 (Catalog # 2470-EL) stimulates proliferation in the TF‑1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Equine IL‑5 (50 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Equine IL‑5 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2470). The ND50 is typically 0.5-2.0 µg/mL.
IL‑5 in Equine PBMCs.
IL‑5 was detected in immersion fixed equine peripheral blood mononuclear cells (PBMCs) treated with calcium ionomycin and PMA using Goat Anti-Equine IL‑5 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2470) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Interleukin-5 (IL-5) is a 40 kDa, secreted, heparin-binding, disulfide-linked homodimeric glycoprotein that belongs to the alpha -helical group of cytokines (1‑3). IL-5 is primarily produced by CD4+ Th2 cells, but other cell types such as eosinophils, endothelial cells, mast cells, visceral (airway) smooth muscle cells, bronchial epithelium, CD16+ NK cells and gamma δ T cells can also produce IL-5. Equine IL-5 is synthesized as a 134 amino acid (aa) precursor that contains a 19 aa signal sequence and a 115 aa mature segment. There are four alpha -helices, two potential N-linked glycosylation sites, and two cysteines that form interchain disulfide bonds with a second, antiparallel IL-5 molecule (3, 4). While human and mouse IL-5 have a potential NLS in their sequence, it is unclear if equine IL-5 has such a sequence. Mature horse IL-5 shares 71%, 89%, 88%, 83%, 66% and 63% aa sequence identity with mature human, bovine, feline, canine, mouse and rat IL-5, respectively.
The receptor for IL-5 consists of a 60 kDa ligand-binding subunit (IL‑5 R alpha ) and a 120 kDa signal-transducing subunit ( beta c). It is suggested that dimeric IL-5 binding to IL‑5 R alpha recruits beta c, which subsequently covalently links with IL‑5 R alpha. This trimeric complex then associates with another trimeric complex to form the physiologic IL-5 receptor (6). Following binding, IL-5 has targeted effects. It promotes the maturation and migration of eosinophils, partially through the effects of eotaxin. It mobilizes eosinophils and CD34+ progenitors from marrow. It also enhances Ig release from B cells and contributes to IL-4 production. Finally, it primes basophils for histamine and leukotriene release (1, 2, 7).
Lalani, T. et al. (1999) Ann. Allergy Asthma Immunol. 82:317.
Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.
Zabeau, L. et al. (2003) Curr. Drug Targets Inflamm. Allergy 2:319.
Vandergrifft, E.V. and D.W. Horohov (1998) GenBank Accession # O02699.
Geijsen, N. et al. (2001) Cytokine Growth Factor Rev. 12:19.
Bagley, C.J. et al. (1997) Blood 89:1471.
Mattes, J. and P.S. Foster (2003) Curr. Drug Targets Inflamm. Allergy 2:169.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.